Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Rhea-AI Summary

Novocure (NVCR) reported strong financial results for Q4 and full year 2024, with total net revenues reaching $605.2 million for the year, up 19% year-over-year. Q4 revenues were $161.3 million, showing a 21% increase.

Key developments include FDA approval of Optune Lua for metastatic non-small cell lung cancer treatment and positive Phase 3 PANOVA-3 trial results for pancreatic cancer. The company maintained 4,126 active patients globally, with 4,077 using Optune Gio for glioblastoma treatment.

Regional Q4 revenues: US ($107.2M), Germany ($17.4M), France ($15.7M), and Japan ($8.5M). Gross margin was 79%. The company reported a quarterly net loss of $65.9 million ($0.61 per share) with adjusted EBITDA of $2.6 million.

Positive

• Revenue growth: 19% YoY increase to $605.2M annual revenue
• FDA approval for Optune Lua in metastatic NSCLC
• Positive Phase 3 PANOVA-3 trial results in pancreatic cancer
• Strong gross margin of 79%
• Healthy cash position of $959.9M

Negative

• Q4 net loss of $65.9M ($0.61 per share)
• Expected low mid-single digit growth rate for 2025
• 84% increase in G&A expenses
• One-time stock compensation expense of $36.1M impacting profits

Insights

Financial Analyst

Novocure's Q4 and full-year 2024 results reveal a company in strategic transition from a single-indication therapy to a multi-indication oncology platform. The 19% year-over-year revenue growth to $605.2 million demonstrates strong commercial execution, particularly in the maturing glioblastoma (GBM) business where management now expects more modest low-to-mid single-digit growth for 2025.

The $161.3 million Q4 revenue includes $8.3 million from prior period claims adjustments, bringing the full-year impact to $22.3 million from improved U.S. approval rates. While these retroactive adjustments boosted 2024 performance, management appropriately excludes them from 2025 baseline projections, suggesting more normalized growth ahead.

The FDA approval of Optune Lua for metastatic non-small cell lung cancer represents a transformative expansion opportunity. With 52 NSCLC prescriptions already received between October approval and year-end, early adoption signals are encouraging for this substantially larger addressable market compared to GBM. This approval triggered $36.1 million in one-time stock compensation expenses, which significantly impacted Q4's $65.9 million net loss.

Most promising is the positive Phase 3 PANOVA-3 trial in pancreatic cancer, which could potentially open a third major revenue stream. Breakthrough Device designations for both pancreatic cancer and brain metastases from NSCLC should accelerate the regulatory pathway for these indications.

The $2.6 million adjusted EBITDA represents a $34.1 million improvement year-over-year, demonstrating operational leverage despite increased commercial investments. With $959.9 million in cash and investments, Novocure is well-positioned to fund both commercial launches and continued clinical development.

Investors should note the planned reporting change from prescriptions to active patients by indication starting Q1 2026, which better aligns with the recurring revenue business model and provides greater visibility into the adoption curve across multiple indications.

Oncology Expert

Novocure's 2024 results mark a pivotal expansion of TTFields therapy beyond its original glioblastoma indication, establishing it as a multi-indication platform with significant clinical validation. The FDA approval of Optune Lua for metastatic NSCLC represents entry into a market nearly 10 times larger than GBM, with approximately 190,000 new NSCLC cases annually in the U.S. alone.

The approval specifically positions TTFields as a concurrent therapy with either immunotherapy (PD-1/PD-L1 inhibitors) or chemotherapy (docetaxel) in the second-line setting. This strategic positioning leverages TTFields' key advantage: localized anti-mitotic effects without adding systemic toxicity, making it an ideal combination partner with established therapies.

The 52 NSCLC prescriptions received in just over two months post-approval represents an encouraging adoption rate, particularly considering the education required for this novel treatment modality. Early patient conversion (20 active patients by year-end) suggests efficient onboarding processes are in place.

The positive Phase 3 PANOVA-3 results in locally advanced pancreatic cancer could be truly transformative. Pancreatic cancer has seen minimal therapeutic advances in decades, with most patients surviving less than one year after diagnosis. Any statistically significant survival improvement in this disease represents a meaningful clinical advancement.

The FDA's Breakthrough Device designations for both pancreatic cancer and brain metastases from NSCLC will accelerate regulatory review, potentially shortening approval timelines by 6-12 months. These designations are granted only when preliminary evidence indicates potential for substantial improvement over existing therapies for life-threatening conditions.

The approval of the Head Flexible Electrode arrays in both U.S. and Japan addresses a critical barrier to TTFields therapy – patient comfort and adherence. The original rigid arrays could cause skin irritation and discomfort, potentially reducing the recommended 18+ hours daily usage. Improved form factors should enhance compliance, which directly correlates with efficacy.

Looking ahead, the PANOVA-4 trial in metastatic pancreatic cancer and TRIDENT trial in newly diagnosed GBM could further expand TTFields' applications, potentially establishing it as a foundational component of cancer care across multiple aggressive tumor types.

Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million

Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial rollout underway in the U.S.

Phase 3 PANOVA-3 trial met primary endpoint, demonstrating statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

“Entering 2024, our team was focused on three objectives – grow our core business treating glioblastoma, launch in non-small cell lung cancer, and deliver on the promise of our clinical pipeline. I am proud to say we have successfully achieved all three goals,” said Ashley Cordova, CEO Novocure. “2025 is a defining year for Novocure as we enter a new era with a multi-indication platform propelled by positive Phase 3 data in three indications – one FDA-approved and two advancing toward regulatory submission. We believe we are positioned to transform patient outcomes across multiple high-need oncology indications.”

Financial updates for the fourth quarter and full year ended December 31, 2024:

• Total net revenues for the year were $605.2 million, an increase of 19% year-over-year, primarily driven by continued launch success in France for Optune Gio^® for glioblastoma (GBM) and improved approval rates in the U.S., which are now reflected in our revenue baseline. 2025 net revenue growth is expected to reflect growth in Optune Gio active patients. As the GBM business reaches maturity we expect to continue to grow at a low mid-single digit rate this year.
• Total net revenues for the quarter were $161.3 million, an increase of 21% year-over-year.
  • The U.S., Germany, France and Japan contributed $107.2 million, $17.4 million, $15.7 million and $8.5 million in quarterly net revenues, respectively, with our other active markets contributing $10.4 million.
  • Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $2.0 million.
  • Improved approval rates in the U.S. resulted in $8.3 million of increased net revenue from prior period claims during the quarter, which we believe should not be considered in our 2025 baseline. This is in addition to the $14.0 million of increased revenue from prior period claims disclosed through the third quarter.
• Gross margin for the quarter was 79%. In 2025, we expect our gross margins will be impacted by current and future product enhancements, such as the U.S. launch of our Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio, and the launch of Optune Lua in metastatic non-small cell lung cancer (NSCLC). Our current analysis of the global tariff environment leads us to believe there should not be a material impact to margins in the short term and we are actively working to mitigate any potential impacts in the medium-to-long term.
• Research, development and clinical studies expenses for the quarter were $51.2 million, a decrease of 6% from the same period in 2023. Clinical trial expenses can fluctuate quarter-to-quarter depending on the number of clinical trials actively underway, amount of clinical research organization services delivered and clinical materials procured.
• Sales and marketing expenses for the quarter were $67.4 million, an increase of 14% from the same period in 2023. This primarily reflects the expansion of our NSCLC sales force as we launch in this new indication.
• General and administrative expenses for the quarter were $72.5 million, an increase of 84% from the same period in 2023. This was primarily driven by $36.1 million in one-time stock-based compensation expenses related to U.S. Food and Drug Administration (FDA) approval of our metastatic NSCLC indication.
• Net loss for the quarter was $65.9 million with loss per share of $0.61.
• Adjusted EBITDA* for the quarter was $2.6 million, an increase of $34.1 million from the same period in 2023. This increase was primarily driven by revenue growth and operational efficiencies.
• Cash, cash equivalents, and short-term investments were $959.9 million as of December 31, 2024.

Operational updates for the fourth quarter ended December 31, 2024:

• As of December 31, 2024, there were 4,126 total active patients on TTFields therapy globally.
• 1,520 Optune Gio prescriptions for the treatment of GBM were received in the quarter, consistent with the same period in 2023. The U.S., Germany, France and Japan contributed 897; 190; 194 and 109 prescriptions, respectively, with the remaining 130 prescriptions contributed by other active markets.
• As of December 31, 2024, there were 4,077 active Optune Gio patients on therapy. The U.S., Germany, France and Japan contributed 2,161; 564; 426 and 420 Optune Gio active patients, respectively, with the remaining 506 active patients contributed by other active markets.
• On October 15, 2024, Optune Lua was approved by the U.S. FDA for the treatment of metastatic NSCLC concurrently with PD-1/PD-L1 inhibitors or docetaxel, in adults who have progressed on or after a platinum-based regimen. Between approval and year end, 52 Optune Lua prescriptions were received for metastatic NSCLC.
• As of December 31, 2024, there were 20 active metastatic NSCLC patients on Optune Lua and 29 active malignant pleural mesothelioma (MPM) patients on Optune Lua.
• Beginning in Q1 2026, Novocure intends to stop reporting new prescriptions received in period and will provide active patients on TTFields therapy by indication and by material market as the key operating statistics.

Fourth quarter and recent updates and achievements:

• In October 2024, the FDA granted Breakthrough Device designation for the use of TTFields therapy for the treatment of brain metastases from NSCLC. Breakthrough Device designation provides more frequent, faster and interactive access to the FDA review team and senior management during the review process, priority review of marketing applications upon filing, and expedited review of pre-Premarket Approval Application (PMA) manufacturing and quality systems compliance inspections.
• In October 2024, the FDA approved Novocure’s new HFE transducer arrays for use with Optune Gio for the treatment of adult patients with GBM.
• In December 2024, the company announced the Phase 3 PANOVA-3 clinical trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer. Novocure plans to submit the full data for presentation at an upcoming medical congress.
• In December 2024, the FDA granted Breakthrough Device designation for the use of TTFields therapy for the treatment of unresectable, locally advanced pancreatic cancer.
• In January 2025, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approved Novocure’s HFE transducer arrays for use with Optune Gio for the treatment of adult patients with GBM.

Anticipated clinical milestones:

• Data from Phase 2 PANOVA-4 clinical trial in metastatic pancreatic cancer (2026)
• Data from Phase 3 TRIDENT clinical trial in newly diagnosed GBM (2026)

Fourth quarter and full year 2024 financial results conference call:

Novocure will host a conference call and webcast to discuss fourth quarter and full year 2024 financial results at 8:00 a.m. EST today, Thursday, February 27, 2025. To access the conference call by phone, use the following conference call registration link, and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The webcast and earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X(Twitter).

*Non-GAAP Financial Measurements

We measure our performance based upon a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation ("Adjusted EBITDA"). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent flings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Consolidated Statements of Operations
USD in thousands (except share and per share data)
		Three Months Ended December 31,								Twelve months ended December 31,
		2024				2023				2024				2023
Net revenues		$	161,266			$	133,784			$	605,220			$	509,338
Cost of revenues			33,466				32,556				137,181				128,280
Gross profit			127,800				101,228				468,039				381,058
Operating costs and expenses:
Research, development and clinical studies			51,210				54,308				209,645				223,062
Sales and marketing			67,411				59,188				239,063				226,809
General and administrative			72,483				39,448				189,827				164,057
Total operating costs and expenses			191,104				152,944				638,535				613,928
Operating income (loss)			(63,304	)			(51,716	)			(170,496	)			(232,870	)
Financial (expenses) income, net			8,098				13,182				39,334				41,130
Income (loss) before income tax			(55,206	)			(38,534	)			(131,162	)			(191,740	)
Income tax			10,716				8,545				37,465				15,303
Net income (loss)		$	(65,922	)		$	(47,079	)		$	(168,627	)		$	(207,043	)
Basic and diluted net income (loss) per ordinary share		$	(0.61	)		$	(0.45	)		$	(1.56	)		$	(1.95	)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share			108,474,919				106,983,693				107,834,368				106,391,178

Consolidated Balance Sheets
USD in thousands (except share data)
		December 31,
		2024			2023
Assets
Current assets:
Cash and cash equivalents		$	163,767		$	240,821
Short-term investments			796,106			669,795
Restricted cash			2,327			1,743
Trade receivables, net			74,226			61,221
Receivables and prepaid expenses			35,063			22,677
Inventories			35,086			38,152
Total current assets			1,106,575			1,034,409
Long-term assets:
Property and equipment, net			77,660			51,479
Field equipment, net			14,811			11,384
Right-of-use assets			27,120			34,835
Other long-term assets			14,618			14,022
Total long-term assets			134,209			111,720
Total assets		$	1,240,784		$	1,146,129

Consolidated Balance Sheets
USD in thousands (except share data)
		December 31,
		2024				2023
Liabilities and shareholders’ equity
Current liabilities:
Convertible note		$	558,160			$	—
Trade payables		$	105,086			$	94,391
Other payables, lease liabilities and accrued expenses			93,130				84,724
Total current liabilities			756,376				179,115
Long-term liabilities:
Convertible note			—				568,822
Senior secured credit facility, net			97,300				—
Deferred revenues			—				—
Long term leases			19,971				27,420
Employee benefit liabilities			6,940				8,258
Other long-term liabilities			18				18
Total long-term liabilities			124,229				604,518
Total liabilities			880,605				783,633
Commitments and contingencies
Shareholders’ equity:
Share capital -
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 108,516,819 shares and 107,075,754 shares at December 31, 2024 and December 31, 2023 respectively;			—				—
Additional paid-in capital			1,519,809				1,353,468
Accumulated other comprehensive income (loss)			(5,500	)			(5,469	)
Retained earnings (accumulated deficit)			(1,154,130	)			(985,503	)
Total shareholders’ equity			360,179				362,496
Total liabilities and shareholders’ equity		$	1,240,784			$	1,146,129

Non-U.S. GAAP financial measures reconciliation
USD in thousands
		Three months ended December 31,											Twelve months ended December 31,
		2023				2022				% Change			2023				2022				% Change
Net income (loss)		$	(65,922	)		$	(47,079	)		40	%		$	(168,627	)		$	(207,043	)		(19	)%
Add: Income tax			10,716				8,545			25	%		$	37,465			$	15,303			145	%
Add: Financial expenses (income), net			(8,098	)			(13,182	)		(39	)%		$	(39,334	)		$	(41,130	)		(4	)%
Add: Depreciation and amortization			3,104				2,723			14	%		$	11,235			$	10,969			2	%
EBITDA		$	(60,200	)		$	(48,993	)		23	%		$	(159,261	)		$	(221,901	)		(28	)%
Add: Share-based compensation			62,757				17,438			260	%		$	160,035			$	115,608			38	%
Adjusted EBITDA		$	2,557			$	(31,555	)		(108	)%		$	774			$	(106,293	)		(101	)%

Active Patients
		December 31,
		2024						2023
		CNS		Lung		Total		CNS		Lung		Total
Active patients at period end*
United States		2,161		31		2,192		2,145		17		2,162
International markets:
Germany		564		11		575		520		5		525
France		426		—		426		262		—		262
Japan		420		—		420		375		—		375
Other international		506		7		513		431		—		431
International markets - Total		1,916		18		1,934		1,588		5		1,593
		4,077		49		4,126		3,733		22		3,755

*Lung includes both active patients in non-small cell lung cancer and malignant pleural mesothelioma (MPM). Worldwide, there were 29 and 22 active MPM patients on therapy as of December 31, 2024 and 2023, respectively.

Important Safety Information

What is Optune Gio ® approved to treat?

Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune Gio is used together with a chemotherapy called temozolomide (TMZ) if:

• Your cancer is confirmed by your healthcare professional AND
• You have had surgery to remove as much of the tumor as possible

Recurrent GBM

If your tumor has come back, Optune Gio can be used alone as an alternative to standard medical therapy if:

• You have tried surgery and radiation and they did not work or are no longer working AND
• You have tried chemotherapy and your GBM has been confirmed by your healthcare professional

Who should not use Optune Gio?

Optune Gio is not for everyone. Talk to your doctor if you have:

• An implanted medical device (programmable shunt), skull defect (missing bone with no replacement), or bullet fragment. Optune Gio has not been tested in people with implanted electronic devices, which may cause the devices not to work properly, and Optune Gio has not been tested in people with skull defects or bullet fragments, which may cause Optune Gio not to work properly
• A known sensitivity to conductive hydrogels (the gel on the arrays placed on the scalp like the ones used on EKGs). When Optune Gio comes into contact with the skin, it may cause more redness and itching or may rarely cause a life-threatening allergic reaction

Do not use Optune Gio if you are pregnant or are planning to become pregnant. It is not known if Optune Gio is safe or effective during pregnancy.

What should I know before using Optune Gio?

Optune Gio should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure^®, the maker of Optune Gio.

• Do not use any parts that did not come with the Optune Gio Treatment Kit sent to you by Novocure or given to you by your doctor
• Do not get the device or transducer arrays wet
• If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune Gio treatment

What are the possible side effects of Optune Gio?

Most common side effects of Optune Gio when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression. The most common side effects when using Optune Gio alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers. Talk to your doctor if you have any of these side effects or questions.

Please visit OptuneGio.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Important Safety Information

What is Optune Lua ® approved to treat?

Optune Lua is a wearable, portable, FDA-approved device used together with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel. It is indicated for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.

Who should not use Optune Lua?

Optune Lua for mNSCLC is not for everyone. Talk to your doctor if you have:

• An electrical implant. Use of Optune Lua together with electrical implants has not been tested and may cause the implanted device not to work properly
• A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergies such as a fall in blood pressure and difficulty breathing
• Do not use Optune Lua if you are pregnant or are planning to become pregnant. It is not known if Optune Lua is safe or effective during pregnancy.

What should I know before using Optune Lua?

Optune Lua should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure^®, the maker of Optune Lua.

• Do not use any parts that did not come with Optune Lua Treatment Kit sent to you by Novocure or given to you by your doctor
• Do not get the device or transducer arrays wet
• Please be aware that Optune Lua has a cord that plugs into an electrical socket. Be careful of tripping when it’s connected
• If you have an underlying serious skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Lua treatment.

What are the possible side effects of Optune Lua?

The most common side effects of Optune Lua when used together with certain immunotherapy and chemotherapy drugs were dermatitis, pain in the muscles, bones, or joints, fatigue, anemia, alopecia (hair loss), dyspnea, nausea, cough, diarrhea, anorexia, pruritus (itching), leukopenia, pneumonia, respiratory tract infection, localized edema (swelling), rash, pain, constipation, skin ulcers, hypokalemia (low potassium levels), hypoalbuminemia (low albumin levels), hyponatremia (low sodium levels), and dysphagia (difficulty swallowing).

Other potential adverse effects associated with the use of Optune Lua include treatment related skin irritation, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown/skin ulcer. Talk to your doctor if you have any of these side effects or questions.

Please visit OptuneLua.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250227102270/en/

INVESTORS:

Ingrid Goldberg

investorinfo@novocure.com

MEDIA:

Catherine Falcetti

media@novocure.com

Source: Novocure

FAQ

What were Novocure's (NVCR) full year 2024 revenue results?

Novocure reported full year 2024 net revenues of $605.2 million, representing a 19% increase year-over-year.

How many active patients were using Novocure's TTFields therapy by end of 2024?

As of December 31, 2024, there were 4,126 total active patients on TTFields therapy globally, with 4,077 specifically using Optune Gio.

What was the outcome of NVCR's Phase 3 PANOVA-3 trial for pancreatic cancer?

The PANOVA-3 trial met its primary endpoint, showing statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer.

What new FDA approval did Novocure (NVCR) receive in October 2024?

Optune Lua received FDA approval for treating metastatic non-small cell lung cancer concurrently with PD-1/PD-L1 inhibitors or docetaxel.

What was NVCR's Q4 2024 financial performance?

Q4 2024 revenues were $161.3 million (+21% YoY), with a gross margin of 79% and net loss of $65.9 million ($0.61 per share).